🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 2 días
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
12/01/2023 1,4800 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/11/2019 85,74 87,27 85,33 86,66 +0,25% 2,26% 5.798.800
12/11/2019 85,60 88,28 85,55 86,44 +0,91% 3,19% 12.165.900
11/11/2019 84,95 85,68 83,90 85,66 +0,53% 2,10% 8.726.300
08/11/2019 82,10 85,46 82,09 85,21 +3,90% 4,10% 11.364.100
07/11/2019 82,21 82,59 81,08 82,01 -0,09% 1,84% 6.561.500
06/11/2019 81,77 82,25 80,35 82,08 +0,29% 2,32% 9.303.600
05/11/2019 83,17 83,40 81,47 81,84 -1,39% 2,32% 7.475.600
04/11/2019 82,95 83,32 82,14 82,99 +1,52% 1,42% 9.127.900
01/11/2019 80,03 82,18 79,13 81,75 +2,77% 3,81% 13.356.300
31/10/2019 79,71 79,74 78,74 79,55 -0,14% 1,25% 10.009.400
30/10/2019 78,51 79,79 78,01 79,66 +1,52% 2,27% 7.222.500
29/10/2019 78,11 78,74 77,59 78,47 +0,18% 1,47% 6.391.500
28/10/2019 76,67 78,38 76,49 78,33 +2,35% 2,47% 7.146.400
25/10/2019 76,39 76,79 76,22 76,53 -0,35% 0,75% 5.497.000
24/10/2019 77,84 77,89 76,25 76,80 -1,22% 2,11% 5.699.300
23/10/2019 77,79 78,02 77,19 77,75 -0,15% 1,07% 6.136.700
22/10/2019 78,05 78,66 77,75 77,87 +0,74% 1,17% 6.062.000
21/10/2019 76,88 77,85 75,85 77,30 +1,10% 2,60% 7.839.100
18/10/2019 75,24 77,17 75,21 76,46 +1,76% 2,60% 9.480.200
17/10/2019 74,99 76,18 74,65 75,14 +0,52% 2,04% 6.811.300
16/10/2019 74,38 74,98 74,34 74,75 +0,34% 0,86% 8.288.300
15/10/2019 74,20 74,98 73,80 74,50 +1,00% 1,59% 6.028.300
14/10/2019 73,65 74,17 73,39 73,76 +0,18% 1,06% 5.040.900
11/10/2019 73,97 74,34 73,57 73,63 -1,10% 1,04% 7.164.900
10/10/2019 73,22 74,63 73,20 74,45 +1,57% 1,95% 7.329.400
09/10/2019 74,07 74,62 73,25 73,30 -0,31% 1,85% 5.851.000
08/10/2019 73,88 74,75 73,42 73,53 -1,08% 1,80% 6.121.500
07/10/2019 74,72 75,27 74,08 74,33 -0,44% 1,59% 5.163.500
04/10/2019 74,22 75,06 73,95 74,66 +1,10% 1,50% 7.007.500
03/10/2019 72,06 73,94 72,04 73,85 +2,38% 2,64% 6.228.500